Clinical Trial Update: Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab [Phase 4]

View source ↗

Summary

A Phase 4 safety study evaluating switching to garadacimab in subjects aged 12 years and older with hereditary angioedema is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Garadacimab (garadacimab)

Snippet

Sponsor: CSL Behring | Conditions: Hereditary Angioedema | Phase 4 | Status: RECRUITING